
    
      This study is a multi-center, single arm, open label trial to evaluate the efficacy and
      safety of Cabozantinib (XL184) plus Pembrolizumab in recurrent, persistent and/or metastatic
      cervical cancer with PD-L1 tumor positivity.
    
  